一种猪胸膜肺炎放线杆菌血清1型减毒突变株的构建及其在疫苗制备中的应用
By constructing the attenuated mutant strain WH01-3A of Actinobacillus pleuropneumoniae, the problem of insufficient cross-protection of existing vaccines was solved, achieving broad-spectrum protection against different serotypes and low-cost vaccine development.
CN120924469BActive Publication Date: 2026-07-17HUAZHONG AGRI UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HUAZHONG AGRI UNIV
- Filing Date
- 2025-08-06
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing Actinobacillus pleuropneumoniae vaccines have limited cross-protective efficacy against different serotypes and are costly, making it difficult to meet the needs of large-scale application.
Method used
A live attenuated mutant strain of Actinobacillus pleuropneumoniae, WH01-3A, was constructed by deleting the apxIV, apxIC, and apxIIC genes and inserting the apxIIIA gene to form an attenuated engineered strain capable of expressing the three toxins, thereby reducing virulence and expanding the scope of cross-protection.
Benefits of technology
It achieves enhanced cross-protection against different serotypes, significantly reduces the virulence of strains, is low in cost and meets biosafety requirements, and has a better immunization effect than existing vaccines.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN120924469B_ABST
Abstract
本发明公开了一种猪胸膜肺炎放线杆菌血清1型减毒突变株的构建及其在疫苗制备中的应用，涉及基因缺失株研究技术领域。包括：通过文献查找，对胸膜肺炎放线杆菌中各个血清型的制毒因子Apx毒素进行研究，通过融合PCR扩增Apx毒素基因上下游同源臂，构建自杀质粒，通过接合转移筛选获得血清1型减毒突变株，该突变菌株与野生型相比，同时表达三种毒素的减毒工程菌株且毒力显著降低，而且其交叉保护范围扩大，关键的是，该突变菌株免疫效果优于MSD疫苗。
Need to check novelty before this filing date? Find Prior Art